siRNA-mediated silencing of Nanog reduces stemness properties and increases the sensitivity of HepG2 cells to cisplatin
| Autor: | Hajar Alemohammad, Rouhollah Motafakkerazad, Zahra Asadzadeh, Nader Farsad, Nima Hemmat, Basira Najafzadeh, Parisa Vasefifar, Behzad Baradaran |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Cell Survival
SOXB1 Transcription Factors Liver Neoplasms Down-Regulation Drug Synergism Hep G2 Cells Nanog Homeobox Protein General Medicine Gene Expression Regulation Neoplastic Hyaluronan Receptors Cell Movement Drug Resistance Neoplasm Biomarkers Tumor Neoplastic Stem Cells Genetics Humans AC133 Antigen Gene Silencing Cisplatin RNA Small Interfering Cell Proliferation |
| Zdroj: | Gene. 821:146333 |
| ISSN: | 0378-1119 |
| DOI: | 10.1016/j.gene.2022.146333 |
| Popis: | Liver cancer is one of the most lethal cancers having worldwide prevalence. Despite significant progress in cancer therapy, liver cancer-induced mortality is very high. Nanog, as an essential transcription factor modulating cellular multipotency, causes tumor progression, drug resistance, and preserves stemness properties in various tumors such as liver cancer. Thus, this research was conducted to evaluate the impact of combination therapy of Nanog siRNA/cisplatin on the sensitivity of liver cancer cells to this drug. HepG2 cells were transfected with Nanog siRNA and treated with cisplatin, individually and in combination. Then, it was observed that in transfected HepG2 cells, Nanog expression was significantly reduced at mRNA level and also these cells were sensitized to cisplatin. In addition, to assess the impact of Nanog siRNA and cisplatin individually and in combination on cells' viability, migration capacity, apoptosis, and cell cycle progression, the MTT, wound healing, colony formation assay, Annexin V/PI staining, and flow cytometry assays were applied on HepG2 cells, respectively. Also, the quantitive Real-Time PCR was used to check the expression of stemness-associated genes (CD44, CD133, and Sox2), and apoptosis-related genes (caspase-3, 8, 9, BAX and Bcl2) after combination therapy. It is indicated that the combination of Nanog siRNA and cisplatin significantly reduced proliferation, migration, and colony formation ability, as well as increased apoptosis rate, and cell cycle arrest. Also, it is found that the combination of Nanog siRNA and cisplatin down-regulated the expression of stemness-associated genes and up-regulated apoptosis-related genes in HepG2 cells. Hence, it can be suggested that Nanog inhibition in combination with cisplatin is a potential therapeutic strategy for developing new therapeutic approaches for liver cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect